Naloxegol: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Rabin Bista (talk | contribs)
nocaptcha, Administrators
4,526 edits
Created page with "{{Drugbox | IUPAC_name = (5α,6α)-17-Allyl-6-[(20-hydroxy-3,6,9,12,15,18-hexaoxaicos-1-yl)oxy]-4,5-epoxymorphinan-3,14-diol | image = Naloxegol.svg | width = | image2 = |..."
 
Rabin Bista (talk | contribs)
nocaptcha, Administrators
4,526 edits
No edit summary
 
Line 1: Line 1:
{{Drugbox
{{Drugbox
| IUPAC_name = (5α,6α)-17-Allyl-6-[(20-hydroxy-3,6,9,12,15,18-hexaoxaicos-1-yl)oxy]-4,5-epoxymorphinan-3,14-diol
| IUPAC_name = (5α,6α)-17-Allyl-6-[(20-hydroxy-3,6,9,12,15,18-hexaoxaicos-1-yl)oxy]-4,5-epoxymorphinan-3,14-diol
| image =  Naloxegol.svg
| image =  Naloxegol.png
| width =   
| width =   
| image2 =  
| image2 =  
Line 53: Line 53:
| routes_of_administration = [[Mouth|Oral]]
| routes_of_administration = [[Mouth|Oral]]
}}
}}
__NOTOC__
{{SI}}
{{CMG}}
== Overview ==
'''Naloxegol''' ([[International Nonproprietary Name|INN]]; '''NKTR-118'''), or '''[[PEGylated]] [[naloxol]]''',<ref name="SeifertWieland2006">{{cite book | author1 = Roland Seifert | author2 = Thomas Wieland | author3 = Raimund Mannhold | coauthors = Hugo Kubinyi, Gerd Folkers | title = G Protein-Coupled Receptors as Drug Targets: Analysis of Activation and Constitutive Activity | url = http://books.google.com/books?id=pIrnOKH-7HcC&pg=PA227 | accessdate = 14 May 2012 | date = 17 July 2006 | publisher = John Wiley & Sons | isbn = 978-3-527-60695-5 | page = 227}}</ref> trade name '''Movantik''', is a [[peripheral nervous system|peripherally]]-[[binding selectivity|selective]] [[opioid antagonist]] under development by [[AstraZeneca]], licensed from Nektar, for the treatment of [[opioid]]-induced [[constipation]].<ref name="Nektar2012">{{cite web | url = http://www.nektar.com/product_pipeline/cns_pain_oral_nktr-118and119.html | title = Nektar &#124; R&D Pipeline &#124; Products in Development &#124; CNS/Pain &#124; Oral Naloxegol (NKTR-118) and Oral NKTR-119 | work = | accessdate = 2012-05-14}}</ref>
'''Naloxegol''' ([[International Nonproprietary Name|INN]]; '''NKTR-118'''), or '''[[PEGylated]] [[naloxol]]''',<ref name="SeifertWieland2006">{{cite book | author1 = Roland Seifert | author2 = Thomas Wieland | author3 = Raimund Mannhold | coauthors = Hugo Kubinyi, Gerd Folkers | title = G Protein-Coupled Receptors as Drug Targets: Analysis of Activation and Constitutive Activity | url = http://books.google.com/books?id=pIrnOKH-7HcC&pg=PA227 | accessdate = 14 May 2012 | date = 17 July 2006 | publisher = John Wiley & Sons | isbn = 978-3-527-60695-5 | page = 227}}</ref> trade name '''Movantik''', is a [[peripheral nervous system|peripherally]]-[[binding selectivity|selective]] [[opioid antagonist]] under development by [[AstraZeneca]], licensed from Nektar, for the treatment of [[opioid]]-induced [[constipation]].<ref name="Nektar2012">{{cite web | url = http://www.nektar.com/product_pipeline/cns_pain_oral_nktr-118and119.html | title = Nektar &#124; R&D Pipeline &#124; Products in Development &#124; CNS/Pain &#124; Oral Naloxegol (NKTR-118) and Oral NKTR-119 | work = | accessdate = 2012-05-14}}</ref>


Line 65: Line 69:
{{Opioidergics}}
{{Opioidergics}}


[[Category:Drugs]]
[[Category:Alkenes]]
[[Category:Alkenes]]
[[Category:Diols]]
[[Category:Diols]]

Latest revision as of 17:06, 9 April 2015

Naloxegol
Clinical data
Trade namesMovantik
AHFS/Drugs.commovantik
[[Regulation of therapeutic goods |Template:Engvar data]]
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • US: Unscheduled
Pharmacokinetic data
Protein binding~4.2%
MetabolismHepatic (CYP3A)
Elimination half-life6–11 h
ExcretionFeces (68%), urine (16%)
Identifiers
CAS Number
PubChem CID
ChemSpider
ChEBI
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC34H53NO11
Molar mass651.785
3D model (JSmol)

WikiDoc Resources for Naloxegol

Articles

Most recent articles on Naloxegol

Most cited articles on Naloxegol

Review articles on Naloxegol

Articles on Naloxegol in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Naloxegol

Images of Naloxegol

Photos of Naloxegol

Podcasts & MP3s on Naloxegol

Videos on Naloxegol

Evidence Based Medicine

Cochrane Collaboration on Naloxegol

Bandolier on Naloxegol

TRIP on Naloxegol

Clinical Trials

Ongoing Trials on Naloxegol at Clinical Trials.gov

Trial results on Naloxegol

Clinical Trials on Naloxegol at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Naloxegol

NICE Guidance on Naloxegol

NHS PRODIGY Guidance

FDA on Naloxegol

CDC on Naloxegol

Books

Books on Naloxegol

News

Naloxegol in the news

Be alerted to news on Naloxegol

News trends on Naloxegol

Commentary

Blogs on Naloxegol

Definitions

Definitions of Naloxegol

Patient Resources / Community

Patient resources on Naloxegol

Discussion groups on Naloxegol

Patient Handouts on Naloxegol

Directions to Hospitals Treating Naloxegol

Risk calculators and risk factors for Naloxegol

Healthcare Provider Resources

Symptoms of Naloxegol

Causes & Risk Factors for Naloxegol

Diagnostic studies for Naloxegol

Treatment of Naloxegol

Continuing Medical Education (CME)

CME Programs on Naloxegol

International

Naloxegol en Espanol

Naloxegol en Francais

Business

Naloxegol in the Marketplace

Patents on Naloxegol

Experimental / Informatics

List of terms related to Naloxegol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Naloxegol (INN; NKTR-118), or PEGylated naloxol,[1] trade name Movantik, is a peripherally-selective opioid antagonist under development by AstraZeneca, licensed from Nektar, for the treatment of opioid-induced constipation.[2]

See also

References

  1. ↑ Roland Seifert; Thomas Wieland; Raimund Mannhold (17 July 2006). G Protein-Coupled Receptors as Drug Targets: Analysis of Activation and Constitutive Activity. John Wiley & Sons. p. 227. ISBN 978-3-527-60695-5. Retrieved 14 May 2012. Unknown parameter |coauthors= ignored (help)
  2. ↑ "Nektar | R&D Pipeline | Products in Development | CNS/Pain | Oral Naloxegol (NKTR-118) and Oral NKTR-119". Retrieved 2012-05-14.

Template:Laxatives


Template:Nervous-system-drug-stub

Retrieved from "https://www.wikidoc.org/index.php?title=Naloxegol&oldid=1085429"